CMS Solicits Ideas To Improve Part D: An Opening For Co-Pay Reform And Shaping Priorities
Executive Summary
The US Medicare agency signals interest in making administrative changes to the Part D drug insurance program in the coming years. That may be an opening for the pharmaceutical industry to push for new approaches to cost-sharing – but it is also an opportunity for plans to try to shape the evolution of Part D in the Trump administration.